

O I P E J C I O
18 2005

FORM PTO-1449/A and B (Modified)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet 1 of 7

APPLICATION NO.: 10/802,440

ATTY. DOCKET NO.: V0139.70060US01

FILING DATE: March 17, 2004

CONFIRMATION NO.: 4035

APPLICANT: Martha K. Newell

GROUP ART UNIT: 1644

EXAMINER: *Vander Vegt* ~~Not Yet Assigned~~

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
<i>R</i>	A1	4,724,234		Cone, Jr.	02-09-1988
	A2	4,935,450		Cone, Jr.	06-19-1990
	A3	5,556,754		Singer et al.	09-17-1996
	A4	5,585,363		Scanlon et al.	12-17-1996
	A5	6,113,946		Cavallaro et al.	10-17-2000
	A6	2003-0150022	A1	Martha et al.	08-07-2003
	A7	2004/00054291	A1	Rogers et al.	01-08-2004
	A8	2005/0074882	A1	Newell	04-07-2005
	A9	2005/0158333	A1	Newell	07-02-2005

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			
<i>R</i>	*B1	WO	98/02579	A1	Emory University	01-22-1998	
	*B2	WO	98/31396	A1	Duke University et al.	07-23-1998	
	*B3	WO	98/45313	A1	Amylin Pharmaceuticals, Inc.	10-15-1998	
	*B4	WO	98/45438	A1	Beth Israel Deaconess Medical Center	10-15-1998	
	B5	WO	99/53953		University of Vermont	10/28/1999	
	*B6	WO	00/47617	A1	Lexicon Genetics, Inc.	08-17-2000	
	B7	WO	00/78941	A2	University of Vermont and State Agricultural College	12-28-2000	
	B5	WO	03/031643	A2	Newell et al.	04/17/2003	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No.	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<i>R</i>	C1	AGRAWAL, S. et al. "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Med. Today</i> , Vol. 6. pp: 72-81, 2000	
	*C2	ARSENIJEVIC et al., Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. <i>Nat Genet.</i> 2000 Dec;26(4):435-9.	
	*C3	ASOH et al., Expression of the apoptosis-mediator Fas is enhanced by dysfunctional mitochondria. <i>J Biochem (Tokyo)</i> . 1996 Sep;120(3):600-7.	
	*C4	BABU et al., Genetic control of multisystem autoimmune disease in encephalomyocarditis virus infected BALB/cCUM and BALB/cBYJ mice. <i>Curr Top Microbiol Immunol.</i> 1985;122:154-61.	
	*C5	BACH et al., Insulin-dependent diabetes mellitus as an autoimmune disease. <i>Endocr Rev.</i> 1994 Aug;15(4):516-42.	

EXAMINER: *[Signature]*


DATE CONSIDERED: 3/20/2006

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/802,440		ATTY. DOCKET NO.: V0139.70060US01	
				FILING DATE: March 17, 2004		CONFIRMATION NO.: 4035	
				APPLICANT: Martha K. Newell			
				GROUP ART UNIT: 1644		EXAMINER: Not Yet Assigned Vander Vegt	
Sheet	3	of	7				

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
PV	*C25	CRAIGHEAD et al., Diverse patterns of immune and non-immune-mediated disease in EMC M-variant-infected mice. J Autoimmun. 1990 Apr;3 Suppl 1:27-9.	
	*C26	CREECH et al., MHC genes modify systemic autoimmune disease. The role of the I-E locus. J Immunol. 1996 Jan 15;156(2):812-7.	
	C27	CROOKE, S. <u>Antisense Research and Application</u> , (Ed. by S. Crooke), pp: 1-50, Springer-Verlag, 1999	
	*C28	DANG et al., Oncogenic alterations of metabolism. Trends Biochem Sci. 1999 Feb;24(2):68-72.	
	*C29	DENIS-POUXVIEL et al., Regulation of mitochondrial hexokinase in cultured HT 29 human cancer cells. An ultrastructural and biochemical study. Biochim Biophys Acta. 1987 Sep 3;902(3):335-48.	
	*C30	DESBARATS et al., Fas (CD95) expression and death-mediating function are induced by CD4 cross-linking on CD4+ T cells. Proc Natl Acad Sci U S A. 1996 Oct 1;93(20):11014-8.	
	*C31	DESBARATS et al., Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat Med. 1998 Dec;4(12):1377-82.	
	C32	ELIOPOULOS, AG et al. "CD40 Stimulation Augments Apoptosis In Carcinoma Cell Lines," J. Cellular Biochem, (supplemental 19B), Abstract B8-123, pg. 271, 1995	
	*C33	FLEURY et al., Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet. 1997 Mar;15(3):269-72.	
	*C34	FREEDMAN et al., gamma delta T-cell-human glial cell interactions. II. Relationship between heat shock protein expression and susceptibility to cytolysis. J Neuroimmunol. 1997 Apr;74(1-2):143-8.	
	*C35	FUJIIHASHI et al., gamma/delta T cell-deficient mice have impaired mucosal immunoglobulin A responses. J Exp Med. 1996 Apr 1;183(4):1929-35.	
	*C36	GARBAN et al., Signal transduction via human leucocyte antigen class II molecules distinguishes between cord blood, normal, and malignant adult B lymphocytes. Exp Hematol. 1998 Aug;26(9):874-84.	
	*C37	GARLID et al., The mechanism of proton transport mediated by mitochondrial uncoupling proteins. FEBS Lett. 1998 Oct 30;438(1-2):10-4.	
	*C38	GENESTIER et al., Caspase-dependent ceramide production in Fas- and HLA class I-mediated peripheral T cell apoptosis. J Biol Chem. 1998 Feb 27;273(9):5060-6.	
	*C39	GOLSHANI-HEBRONI et al., Hexokinase binding to mitochondria: a basis for proliferative energy metabolism. J Bioenerg Biomembr. 1997 Aug;29(4):331-8.	
	*C40	GONZÁLEZ-BARROSO et al., The uncoupling protein UCP1 does not increase the proton conductance of the inner mitochondrial membrane by functioning as a fatty acid anion transporter. J Biol Chem. 1998 Jun 19;273(25):15528-32.	
	*C41	GORER et al., The genetic and antigenic basis of tumour transplantation. J Pathol. 1937;44:691-7.	
	*C42	GRAY et al., Mitochondrial evolution. Science. 1999 Mar 5;283(5407):1476-81.	
	*C43	GREINER et al., Glucose is essential for proliferation and the glycolytic enzyme induction that provokes a transition to glycolytic energy production. J Biol Chem. 1994 Dec 16;269(50):31484-90.	
	*C44	HARPER et al., Use of top-down elasticity analysis to identify sites of thyroid hormone-induced thermogenesis. Proc Soc Exp Biol Med. 1995 Mar;208(3):228-37.	

EXAMINER:




DATE CONSIDERED:

3/20/2006

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/802,440		ATTY. DOCKET NO.: V0139.70060US01	
				FILING DATE: March 17, 2004		CONFIRMATION NO.: 4035	
				APPLICANT: Martha K. Newell			
				GROUP ART UNIT: 1644		EXAMINER: Not Yet Assigned VanderKest	
Sheet	4	of	7				

OTHER ART — NON PATENT LITERATURE DOCUMENTS


Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
P	*C45	HATEFI et al., Nicotinamide nucleotide transhydrogenase: a model for utilization of substrate binding energy for proton translocation. FASEB J. 1996 Mar;10(4):444-52.	
	*C46	HAYNES et al., Helper-inducer T-lymphocytes mediate diabetes in EMC-infected BALB/c ByJ mice. Diabetes. 1987 Jul;36(7):877-81.	
	*C47	HERMESH et al., Mitochondria uncoupling by a long chain fatty acyl analogue. J Biol Chem. 1998 Feb 13;273(7):3937-42.	
	*C48	HESS et al., Cooperation of glycolytic enzymes. Adv Enzyme Regul. 1969;7:149-67.	
	*C49	HIMMS-HAGEN et al., Chapter 2: Brown adipose tissue metabolism. in Obesity. Per Björntorp et al., eds. J.B. Lippincott Company, Philadelphia, PA: 1992. p15-34.	
	*C50	HOSOKAWA et al., Beta-cell hypersensitivity to glucose following 24-h exposure of rat islets to fatty acids. Diabetologia. 1997 Apr;40(4):392-7.	
	*C51	HUBER et al., Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J Virol. 1994 Aug;68(8):5126-32.	
	*C52	HUBER et al., Modulation of cytokine expression by CD4+ T cells during coxsackievirus B3 infections of BALB/c mice initiated by cells expressing the gamma delta + T-cell receptor. J Virol. 1996 May;70(5):3039-44.	
	*C53	KANG et al., Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med. 1997 Jul;3(7):738-43.	
	*C54	KENNEDY et al., Effects of depletion of mitochondrial DNA in metabolism secretion coupling in INS-1 cells. Diabetes. 1998 Mar;47(3):374-80.	
	*C55	KIBERSTIS et al., Mitochondria make a comeback. Science. 1999 Mar 5;283(5407):1475.	
	*C56	KORSHUNOV et al., Fatty acids as natural uncouplers preventing generation of O2.- and H2O2 by mitochondria in the resting state. FEBS Lett. 1998 Sep 18;435(2-3):215-8.	
	*C57	LARROUY et al., Kupffer cells are a dominant site of uncoupling protein 2 expression in rat liver. Biochem Biophys Res Commun. 1997 Jun 27;235(3):760-4.	
	*C58	LEFRANCOIS et al., Extrathymic selection of TCR gamma delta + T cells by class II major histocompatibility complex molecules. Cell. 1990 Oct 19;63(2):333-40.	
	*C59	LE MEUR et al., Correcting an immune-response deficiency by creating E alpha gene transgenic mice. Nature. 1985 Jul 4-10;316(6023):38-42.	
	*C60	LE MEUR et al., Restricted assembly of MHC class II molecules in transgenic mice. J Immunol. 1989 Jan 1;142(1):323-7.	
	*C61	LEE et al., HLA-DR-mediated signals for hematopoiesis and induction of apoptosis involve but are not limited to a nitric oxide pathway. Blood. 1997 Jul 1;90(1):217-25.	
	C62	LOBATO, M. et al. "Intracellular antibodies and challenges facing their use as therapeutic agents," Trends in Molecular Medicine," Vol 9, No. 9, pp: 390-396, 2003	
	*C63	LOGAN et al., A glycyl radical site in the crystal structure of a class III ribonucleotide reductase. Science. 1999 Mar 5;283(5407):1499-504.	
	*C64	LOUDON et al., An attenuated variant of Coxsackievirus B3 preferentially induces immunoregulatory T cells in vivo. J Virol. 1991 Nov;65(11):5813-9.	
	*C65	LUFT et al., Mitochondrial medicine. J Intern Med. 1995 Nov;238(5):405-21.	
	*C66	LÜHDER et al., Major histocompatibility complex class II molecules can protect from diabetes by positively selecting T cells with additional specificities. J Exp Med. 1998 Feb 2;187(3):379-87.	

EXAMINER: 	DATE CONSIDERED: 3/20/06
--------------------------------------------------------------------------------------------------	-----------------------------

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/802,440		ATTY. DOCKET NO.: V0139.70060US01	
				FILING DATE: March 17, 2004		CONFIRMATION NO.: 4035	
				APPLICANT: Martha K. Newell			
				GROUP ART UNIT: 1644		EXAMINER: Not Yet Assigned <i>VanderVegt</i>	
Sheet	5	of	7				


OTHER ART — NON PATENT LITERATURE DOCUMENTS


Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
19	*C67	MACKANESS et al., The J. Burns Amberson LECTURE The induction and expression of cell-mediated hypersensitivity in the lung. Am Rev Respir Dis. 1971 Dec;104(6):813-28.	
	*C68	MARZO et al., Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science. 1998 Sep 25;281(5385):2027-31.	
	*C69	MAURICIO et al., Apoptosis and the pathogenesis of IDDM: a question of life and death. Diabetes. 1998 Oct;47(10):1537-43.	
	*C70	MEUER et al., Cellular signalling in T lymphocytes. Immunol Today. 1989 Aug;10(8):S23-5.	
	*C71	MEYER et al., Giant cell myocarditis due to coxsackie B2 virus infection. Cardiology. 1997 May-Jun;88(3):296-9.	
	*C72	MIEZA et al., Selective reduction of V alpha 14+ NK T cells associated with disease development in autoimmune-prone mice. J Immunol. 1996 May 15;156(10):4035-40.	
	*C73	MORIMOTO et al., Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins. Cancer Res. 1993 Jun 1;53(11):2591-6.	
	*C74	NAKAMOTO et al., Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 1998 Jul 20;188(2):341-50.	
	*C75	NÈGRE-SALVAYRE et al., A role for uncoupling protein-2 as a regulator of mitochondrial hydrogen peroxide generation. FASEB J. 1997 Aug;11(10):809-15.	
	*C76	NEWELL et al., Biochemical characterization of proteins that co-purify with class II antigens of the murine MHC. J Immunol. 1988 Mar 15;140(6):1930-8.	
	*C77	NEWELL et al., Death of mature T cells by separate ligation of CD4 and the T-cell receptor for antigen. Nature. 1990 Sep 20;347(6290):286-9.	
	*C78	NEWELL et al., Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10459-63.	
	C79	PALU, G. et al. "In pursuit of new developments for gene therapy of human diseases," <i>Journal of Biotech</i> , Vol. 68, pp: 1-13, 1999	
	C80	PIHL-CAREY, K. "Disease Drug Fails in Phase III," <i>BioWorld Today</i> , Vol. 10, pp: 1-2, 1999	
	*C81	PECQUEUR et al., Uncoupling protein 2, in vivo distribution, induction upon oxidative stress, and evidence for translational regulation. J Biol Chem. 2001 Mar 23;276(12):8705-12. Epub 2000 Nov 29.	
	*C82	POSSELT et al., Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science. 1990 Sep 14;249(4974):1293-5.	
*C83	REYES et al., The proinflammatory cytokine network: interactions in the CNS and blood of rhesus monkeys. Am J Physiol. 1998 Jan;274(1 Pt 2):R139-44.		
*C84	RUIZ-RUIZ et al., Activation of protein kinase C attenuates early signals in Fas-mediated apoptosis. Eur J Immunol. 1997 Jun;27(6):1442-50.		
*C85	RUSTENBECK et al., Energetic requirement of insulin secretion distal to calcium influx. Diabetes. 1997 Aug;46(8):1305-11.		
*C86	SARASTE et al., Oxidative phosphorylation at the fin de siecle. Science. 1999 Mar 5;283(5407):1488-93.		

EXAMINER: 	DATE CONSIDERED: <i>3/20/06</i>
--------------------------------------------------------------------------------------------------	------------------------------------

FORM PTO-1449/A and B (Modified)				APPLICATION NO.: 10/802,440		ATTY. DOCKET NO.: V0139.70060US01	
				FILING DATE: March 17, 2004		CONFIRMATION NO.: 4035	
				APPLICANT: Martha K. Newell			
				GROUP ART UNIT: 1644		EXAMINER: Not Yet Assigned VanderKest	
Sheet	6	of	7				

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	*C87	SATOH et al., Changes in mitochondrial membrane potential during oxidative stress-induced apoptosis in PC12 cells. J Neurosci Res. 1997 Nov 1;50(3):413-20.	
	*C88	SCAFFIDI et al., Two CD95 (Apo-1/Fas) signaling pathways. EMBO J. 1998 Mar 16;17(6):1675-87.	
	*C89	SCHATTNER et al., CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. J Exp Med. 1995 Nov 1;182(5):1557-65.	
	*C90	SCHILD et al., The nature of major histocompatibility complex recognition by gamma delta T cells. Cell. 1994 Jan 14;76(1):29-37.	
	*C91	SCHREZENMEIER et al., Inactivation of a T cell receptor-associated GTP-binding protein by antibody-induced modulation of the T cell receptor/CD3 complex. J Exp Med. 1988 Aug 1;168(2):817-22.	
	*C92	SCIORATI et al., Autocrine nitric oxide modulates CD95-induced apoptosis in gammadelta T lymphocytes. J Biol Chem. 1997 Sep 12;272(37):23211-5.	
	*C93	SKERRETT et al., New transplant method evades immune attack. Science. 1990 Sep 14;249(4974):1248.	
	*C94	SNELL et al., Some recollections of Peter Gorer and his work on this fiftieth anniversary of his discovery of H-2. Immunogenetics. 1986;24(6):339-40.	
	*C95	SNELL et al., The Nobel Lectures in Immunology. Lecture for the Nobel Prize for Physiology or Medicine, 1980: Studies in histocompatibility. Scand J Immunol. 1992 Oct;36(4):513-26.	
	C96	STAYTON, P. et al. "Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics," <i>Journal of Controlled Releases</i> , Vol. 65, pp: 203-220, 2000	
	*C97	STREET et al., Interferon-gamma enhances susceptibility of cervical cancer cells to lysis by tumor-specific cytotoxic T cells. Gynecol Oncol. 1997 May;65(2):265-72.	
	*C98	SUMMERFIELD et al., Lymphocyte apoptosis during classical swine fever: implication of activation-induced cell death. J Virol. 1998 Mar;72(3):1853-61.	
	*C99	SUZUKI et al., Maximal proliferation of cytotoxic T lymphocytes requires reverse signaling through Fas ligand. J Exp Med. 1998 Jan 5;187(1):123-8.	
	*C100	TANEJA et al., Expression of the H2-E molecule mediates protection to collagen-induced arthritis in HLA-DQ8 transgenic mice: role of cytokines. Int Immunol. 1997 Aug;9(8):1213-9.	
	*C101	TERUYA et al., Pancreatic islet function in nondiabetic and diabetic BB rats. Diabetes. 1993 Sep;42(9):1310-7.	
	*C102	TIAN et al., Attenuation of inducible Th2 immunity with autoimmune disease progression. J Immunol. 1998 Nov 15;161(10):5399-403.	
	*C103	TRUMAN et al., HLA class II-mediated death is induced via Fas/Fas ligand interactions in human splenic B lymphocytes. Blood. 1997 Mar 15;89(6):1996-2007.	
	*C104	TRUMAN et al., HLA class II signaling mediates cellular activation and programmed cell death. Exp Hematol. 1996 Oct;24(12):1409-15.	
	*C105	VIDAL-PUIG et al., Uncoupling expectations. Nat Genet. 2000 Dec;26(4):387-8.	
	*C106	WALLACE et al., Mitochondrial diseases in man and mouse. Science. 1999 Mar 5;283(5407):1482-8.	
	*C107	WILKENS et al., ATP synthase's second stalk comes into focus. Nature. 1998 May 7;393(6680):29.	

EXAMINER: 	DATE CONSIDERED: 3/29/06
--------------------------------------------------------------------------------------------------	-----------------------------

FORM PTO-1449/A and B (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICATION NO.: 10/802,440	ATTY. DOCKET NO.: V0139.70060US01
		FILING DATE: March 17, 2004	CONFIRMATION NO.: 4035
		APPLICANT: Martha K. Newell	
		GROUP ART UNIT: 1644	EXAMINER: Not Yet Assigned <i>VanderVest</i>
Sheet	7 8	of	7

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
<i>ma</i>	*C108	YAFFE et al., The machinery of mitochondrial inheritance and behavior. Science. 1999 Mar 5;283(5407):1493-7.	
	*C109	ZHANG et al., LAT: the ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation. Cell. 1998 Jan 9;92(1):83-92.	
	*C110	ZINKERNAGEL et al., The discovery of MHC restriction. Immunol Today. 1997 Jan;18(1):14-7.	

EXAMINER: <i>[Signature]</i>	DATE CONSIDERED: <i>3/20/06</i>
---------------------------------	------------------------------------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/711,022, filed November 9, 2000 or Serial No. 09/277,575, filed March 27, 1999, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office hereby waives the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003. See 37 CFR 1.491(b). For all patent applications filed on or before June 30, 2003, copies of cited U.S. patents and patent application publications are still required unless an eIDS is filed. Copies of all other patent(s), publication(s), or other information listed must still be provided, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]